{
    "title": "AstraZeneca shares rise as trial shows drug could help prolong life of terminally ill prostate cancer patients",
    "url": "https://www.dailymail.co.uk/money/markets/article-10514799/AstraZeneca-shares-rise-positive-results-cancer-drug-trial.html",
    "date": "2022-02-15",
    "keywords": [
        "cancer",
        "cent",
        "drug",
        "treatment",
        "prostate",
        "progression",
        "time",
        "astrazeneca",
        "trial",
        "disease",
        "lynparza",
        "uk",
        "dividend",
        "decade",
        "share",
        "fund",
        "giant",
        "ftse",
        "combination",
        "market",
        "year",
        "risk",
        "investment",
        "account",
        "fee",
        "today",
        "latestage",
        "cancerthe",
        "group",
        "hormone",
        "therapy",
        "standard",
        "carethis",
        "firstline",
        "quality",
        "life",
        "executive",
        "vice",
        "president",
        "oncology",
        "rd",
        "closethe",
        "jump",
        "heavyweight",
        "stock",
        "mostcommon",
        "globearound",
        "lifetime",
        "claiming",
        "charity",
        "force",
        "business",
        "woe",
        "article",
        "breast",
        "success",
        "jefferiesthey",
        "opportunity",
        "phase3",
        "death",
        "trend",
        "survivalroy",
        "officer",
        "research",
        "health",
        "possibleit",
        "week",
        "record",
        "pharma",
        "covid19",
        "vaccine",
        "diy",
        "capital",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}